The nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, has demonstrated effectiveness in slowing the progression of kidney disease in patients with type 2 diabetes mellitus [21,22]. Here, NR3C2 is linked to kidney disorder.